FINGER LENGTH – A reliable predictor for prostate cancer?
December 29, 2010
Earlier this month, British researchers published new research presenting a link between the relative length of the index finger and the risk of developing prostate cancer. In men with an index finger longer than the ring finger the chances are 33% higher for not developing the disease.
Often such studies are qualified by non-experts as “nonsense” – initially because of the association with classical palmistry. Usually a main argument of concern is the seize of the studied sample: many ‘2D:4D digit ratio’ studies have been focused relatively small samples, and usually with the statistics were simly not strong enough to be applied to individuals. But those arguments can not be used to the describe the new British study!
The new British research involves a study where the hands of 1,524 prostate cancer patients were examined, which were compared with a control group of 3,044 men.
It can also be noted that Professor John Manning described in his second book ‘The Finger Book‘ with great details the suspected link between the ‘2D:4D digit ratio’ and prostate cancer – a complex theory about of role glutamine chains in the sensitivity of hormone receptors, which in their turn play a role in the activation of testosterone in the body:
“…The various forms of the androgen receptor have important consequences for our health and behaviour. For example, African-American men have shorter glutamine chains (high sensitivity to testosterone) than white men. Short glutamine chains are associated with an increased susceptibility to prostate cancer, and this may in part explain why the incidence of prostate cancer is higher in African-Americans than in white Americans. …”
In short, there seems to exist a triangular relationship between: 1) the high percentage of prostate cancer in Americans with African ancestry, 2) the length of the glutamine chains, and 3) the length ratio between index finger and ring finger.
The importance of the new British study can be recognized in the fact the use of preventive screening for prostate cancer – which is anno 2010 usually done through the use of a blood test – is still an object of confusion. Simply because the benefits of the screening devices are still very unclear. Meanwhile it is a fact that prostate cancer is known as the No. 1 cause of death from cancer in men (see picture below).
The British researchers therefore are speculating about how to add a practical application of their finger length study to the traditional methods of prostate cancer prevention screening!